Navigation Links
Endo Pharmaceuticals Introduces VALSTAR(TM) (Valrubicin) To Fill Unmet Need In Aggressive Form of Bladder Cancer
Date:9/3/2009
ure events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors could affect our future financial results and could cause our actual results to differ materially from those expressed in forward-looking statements contained in this press release. These factors include, but are not limited to those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K, particularly the discussion under the caption "Item 1A, RISK FACTORS" in our annual report on Form 10-K for the year ended December 31, 2008, which was filed with the Securities and Exchange Commission on March 2, 2009. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, we think could cause our actual results to differ materially from expected and historical results. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
'/>"/>
| SOURCE Endo Pharmaceuticals Copyright©2009 PR Newswire. All rights reserved |
Related medicine news :
1. Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2010
2. Isis Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference 2009
3. Endo Pharmaceuticals Gives Update on Regulatory Status of Testosterone Undecanoate for Men with Hypogonadism
4. DUSA Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
5. Transdel Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference
6. MAP Pharmaceuticals to Present at Upcoming Healthcare and Scientific Conferences
7. Lexicon Pharmaceuticals to Present at the Thomas Weisel Partners Healthcare Conference
8. EPIX Pharmaceuticals, Inc. Announces the P2Y2 Gastrointestinal Early Development Candidate Program Will Be Part of the Intellectual Property Offered For Sale at the September 30, 2009 Auction
9. Cumberland Pharmaceuticals to Present at UBS Global Life Sciences Conference in New York on September 21, 2009
10. Endo Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference 2009
11. Keryx Biopharmaceuticals, Inc. To Present at the Rodman & Renshaw Annual Global Investment Conference and To Hold Investor/Analyst Day
Post Your Comments:
(Date:5/21/2013)... The Special Olympics Missouri State Summer Games ... the state to Columbia. This state-level event takes place May ... and Columbia College, and at Hickman High School and Town ... kick off at 7:30 p.m. Friday, May 30 with the ... theme, the Parade of Athletes, the culmination of the statewide ...
(Date:5/21/2013)... Venice Beach, Calif. (PRWEB) May 21, 2013 ... to treating a dual diagnosis of Borderline Personality Disorder ... therapy that is proving to be successful for the ... Saturday, June 1, Alina Gorgorian, Ph.D., clinical director ... treatment in Los Angeles, will provide attendees of ...
(Date:5/21/2013)... autism showed significant improvement after six months of simple ... scents, spoons and sponges, according to UC Irvine neurobiologists. ... enrichment led to notable gains in male subjects between ... in Behavioral Neuroscience . , Study co-authors Cynthia ... one of two groups, balanced for age and autism ...
(Date:5/21/2013)... 2013 STAR (Sensory Therapies And ... with sensory challenges and the Sensory Processing Disorder ... and advocacy of Sensory Processing Disorder present Stumbling Blocks ... Improve Quality of Life, a two-hour lecture presented by ... , Learn a method that can aid in ...
(Date:5/21/2013)... Chicago, IL (PRWEB) May 21, 2013 ... business process integration solutions, today announced it is the ... by analyst firm 451 Research. The report, “Adeptia Bets ... in-depth review of the company, its strategy, products, pricing, ... are in need of a framework for integration and ...
Breaking Medicine News(10 mins):Health News:Special Olympics Missouri Athletes Ready to Show Off Skills in Columbia 2Health News:Special Olympics Missouri Athletes Ready to Show Off Skills in Columbia 3Health News:Clearview Treatment Programs Clinical Director to Present on DBT and Substance Abuse at WCSAD 2Health News:Clearview Treatment Programs Clinical Director to Present on DBT and Substance Abuse at WCSAD 3Health News:Enrichment therapy effective among children with autism, UCI study finds 2Health News:STAR Center and SPD Foundation Present a Lecture on Teens and Adults with Sensory Processing Disorder 2Health News:STAR Center and SPD Foundation Present a Lecture on Teens and Adults with Sensory Processing Disorder 3Health News:Adeptia Featured in Recent 451 Research Impact Report 2[0] Special Olympics Missouri Athletes Ready to Show Off Skills in Columbia[0] Clearview Treatment Programs Clinical Director to Present on DBT and Substance Abuse at WCSAD[0] Enrichment therapy effective among children with autism, UCI study finds[0] STAR Center and SPD Foundation Present a Lecture on Teens and Adults with Sensory Processing Disorder[0] Adeptia Featured in Recent 451 Research Impact Report
... common condition, researchers say , TUESDAY, March 30 (HealthDay News) ... deep vein thrombosis, it is most likely to occur on ... researchers have found. , Dr. Wee-Shian Chan of Women,s ... review, said in a news release that the clots most ...
... Osmosis Day ... business with more than 200,000 of the unique healing bath treatments delivered in a Japanese ... Freestone, CA (PRWEB) ... chicken coop, Osmosis, a day spa in Sonoma County California , has delivered more ...
... from arthritis and osteoporosis to broken bones that won,t ... a key molecular player to keep stem cells in ... makes treatment with the cells in the future more ... the cells, known as mesenchymal (pronounced meh-ZINK-a-mill) stem cells, ...
... and the American Society of Hematology (ASH) have selected ... EHA-ASH Research Exchange Award, which serves to strengthen ties ... Ingmar Bruns is a resident physician and research scientist ... at the University of Dsseldorf in Germany. After graduating ...
... ... Serve Spanish-Speaking Patients , ... (PRWEB) March 30, 2010 -- The HealthLinkRx Institute has announced news dates ... sessions of the Institute’s “Therapy in Spanish” class will be offered in Austin, TX ...
... , TUESDAY, March 30 (HealthDay News) -- Researchers have ... be linked to autism disorders. , "To our knowledge, ... of association between these important genes in brain connections ... of the Wellcome Trust Center for Human Genetics at ...
Cached Medicine News:Health News:California Day Spa - Osmosis Celebrates 25th Anniversary With Over 200,000 Cedar Enzyme Baths Given 2Health News:California Day Spa - Osmosis Celebrates 25th Anniversary With Over 200,000 Cedar Enzyme Baths Given 3Health News:Promoting healing by keeping skeletal stem cells 'young' 2Health News:Promoting healing by keeping skeletal stem cells 'young' 3Health News:European hematologist receives award to conduct research in US 2Health News:HealthLinkRx Announces Classes in Spanish for Occupational and Physical Therapists 2In Pregnancy, Leg Clots More Likely on Left SideCalifornia Day Spa - Osmosis Celebrates 25th Anniversary With Over 200,000 Cedar Enzyme Baths GivenPromoting healing by keeping skeletal stem cells 'young'European hematologist receives award to conduct research in USHealthLinkRx Announces Classes in Spanish for Occupational and Physical Therapists Susceptibility to Autism Tied to Genes
(Date:5/21/2013)... May 21, 2013 Accuray Incorporated ... publication of study results involving hundreds of prostate ... System, the most widely used form of prostate ... 304 patients for a median of 5 years, ... that 97 percent of patients with low-risk and ...
(Date:5/21/2013)... Fla. , May 21, 2013 Janssen ... safety results from the global Phase 3 PROMISE ... inhibitor simeprevir (TMC435) led to sustained virologic response ... in 79 percent of treatment-experienced genotype 1 chronic ... including all stages of liver fibrosis, when administered ...
(Date:5/21/2013)... 21, 2013 Abaxis, Inc. (NasdaqGS: ABAX), a ... today that Martin Mulroy , chief ... Dental & Veterinary Conference on Wednesday, May 29, 2013 ... at Le Parker Meridien Hotel in New ... Abaxis develops, manufactures, markets and sells portable blood ...
Breaking Medicine Technology:New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 2New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2[0] New Data Validates CyberKnife SBRT for Prostate Cancer Treatment[0] Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients[0] Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference
... May 7 Patients treated with the ... at two years, according to interim results from ... a late-breaking clinical trial at the Society for ... Sessions. The prospective, single-arm study is ongoing to ...
... Inc. (NYSE: HRC ) today announced its fiscal 2010 third quarter dividend of ... 6, 2010 , and is payable on June 30, 2010 , to shareholders of record ... , , ABOUT ... Hill-Rom is a leading worldwide manufacturer and ...
Cached Medicine Technology:Drug-Eluting Peripheral Stent Continues to Show Positive Data at Two Years 2Drug-Eluting Peripheral Stent Continues to Show Positive Data at Two Years 3... Olympus has pioneered the ... neurosurgical imaging system, an innovative ... be more efficient and less ... consists of the OME-7000 surgical ...
The Leica MS1 F/MC1 F is designed to mount on the ceiling with a high degree of mobility. Its unique and patented suspension concept assures a superior stability and a perfect and steady microscope i...
... SheerVision surgical magnifying loupes are ... quality optics which provide the healthcare ... and greater depth of field. Each ... in a fully lined wooden box ...
... Advantage delivers higher magnification for advanced surgical ... image, even at the highest magnification. 3.5x, ... and precise color rendition is ideal for ... anti-reflective coating produce a superior image. The ...
Medicine Products:| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |